Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer
Pembrolizumab, an inhibitor target programmed death 1 (PD-1), was approved into the first line therapy in advanced non-small cell lung cancer (NSCLC). It was a milestone that immune checkpoints drugs have played an important role in the treatment system of NSCLC. The results of clinical trials revea...
Main Authors: | Zhansheng JIANG, Zhanyu PAN, Xiubao REN |
---|---|
Format: | Article |
Language: | zho |
Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2017-02-01
|
Series: | Chinese Journal of Lung Cancer |
Subjects: | |
Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2017.02.09 |
Similar Items
-
Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01) -
Advances of the Role of Lung Cancer Driver Gene and PD-1/PD-L1 Pathway Interaction in the Tumorigenesis and Progression of Non-small Cell Lung Cancer
by: Yan SHI, et al.
Published: (2017-11-01) -
Advances of PD-1/PD-L1 Signaling Pathway in Immune Escape and Treatment for
Non-small Cell Lung Cancer
by: Cheng LIN, et al.
Published: (2014-10-01) -
Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations
by: Ling JIANG, et al.
Published: (2021-09-01) -
Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids
by: Mingbiao LI, et al.
Published: (2016-12-01)